New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis

Published:2018-08-02 Issue:3 Volume:5 Page:265-277
ISSN:2214-3599
Container-title:Journal of Neuromuscular Diseases
language:
Short-container-title:JND

Author:

Behin Anthony¹²,Le Panse Rozen³⁴²

Affiliation:

1. APHP, Centre de Référence des Maladies Neuromusculaires Nord/Est/Ile-de-France, Institut de Myologie, GH Pitié-Salpêtrière, Paris, France

2. AIM, Institut de Myologie, Paris, France

3. INSERM U974, Paris, France

4. UPMC Sorbonne Université, Paris, France

Publisher

IOS Press

Subject

Neurology (clinical),Neurology

Reference102 articles.

1. Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis;Aharonov;Lancet,1975

2. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies;Hoch;Nat Med,2001

3. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis;Higuchi;Ann Neurol,2011

4. Diagnostic and clinical classification of autoimmune myasthenia gravis;Berrih-Aknin;J Autoimmun,2014

5. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor;Tzartos;J Neuroimmunol,1987

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients;Frontiers in Neurology;2024-06-17

2. Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod;Frontiers in Immunology;2024-06-07

3. Treating myasthenia gravis beyond the eye clinic;Eye;2024-05-24

4. Rozanolixizumab: A New Therapy in the Treatment of Myasthenia Gravis;Annals of Pharmacotherapy;2024-03-27

5. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis;Frontiers in Neurology;2024-01-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3